论文部分内容阅读
目的:探讨比卡鲁胺治疗前列腺癌的疗效和安全性。方法:2006年7月1日至2008年6月30日间,以我科收治的不能根治的52例前列腺癌患者为对象,全部患者至少符合下述1个条件:高龄体弱、局部肿瘤浸润膀胱颈或精囊无法手术切除、伴有骨转移或盆腔淋巴结广泛转移。患者口服比卡鲁胺50mg,qd,结合手术或药物去势,每月随访前列腺特异性抗原(PSA)及血常规、肝肾功能,连续治疗12个月之后,根据PSA水平采用间歇治疗。平均随访时间18个月,观察患者的疼痛缓解及肿瘤消退情况。结果:开始治疗后,52例患者的PSA均下降。随访1年时,有45例达到0.1ng·mL-1以下;另外7例下降不满意,采用其他治疗。无因明显肝肾功能损害而停药的患者。随访至发稿时,46例存活,3例死于前列腺癌进展,3例死于其他疾病。结论:比卡鲁胺结合手术或药物去势治疗不能根治的前列腺癌,可在较短时间内改善前列腺癌患者的症状,疗效肯定,不良反应轻微。
Objective: To investigate the efficacy and safety of bicalutamide in the treatment of prostate cancer. Methods: From July 1, 2006 to June 30, 2008, 52 cases of prostate cancer treated by our department were treated. All of the patients met at least one of the following conditions: elderly and infirm, local tumor infiltration Bladder neck or seminal vesicle can not be surgically removed, with bone metastases or pelvic lymph node metastasis. Patient oral bicalutamide 50mg, qd, combined with surgical or drug castration, monthly follow-up of prostate-specific antigen (PSA) and blood, liver and kidney function, continuous treatment for 12 months, according to PSA level intermittent treatment. The average follow-up time was 18 months. The pain relief and tumor regression were observed. Results: PSA was decreased in 52 patients after treatment was started. One year follow-up, 45 patients reached 0.1ng · mL-1 or less; the other seven were not satisfied with the decline, the use of other treatments. No due to significant liver and kidney dysfunction and withdrawal of patients. At follow-up to press time, 46 survived, 3 died of prostate cancer, and 3 died of other illnesses. Conclusion: Bicalutamide in combination with surgery or drug castration for the treatment of unresectable prostate cancer can improve the symptoms of prostate cancer patients in a relatively short period of time. The curative effect is definite and the adverse reactions are mild.